lobbying_activities: 3188060

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3188060	6cb41732-f98c-4ac9-948f-699318899057	Q2	MARSHALL & POPP, LLC	401105121	AMGEN USA INC.	2024	second_quarter	CPT	Issues related to intellectual property and patent reform, including: S. 150, Affordable Prescriptions for Patients Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 113, Prescription Pricing for the People Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; and S. 148, Stop STALLING Act. Issues related to the National Institute of Standards and Technology request for public comment on a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights.	HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2024-07-10T14:48:35-04:00